Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alex Shimmings
The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.
The results of the POLO trial, showing a benefit of Myriad’s BRACAnalysis CDx companion diagnostic for AstraZeneca’s Lynparza (olaparib) to treat pancreatic cancer offer more support for the new guidelines from the National Comprehensive Cancer Network recommending genetic testing for all pancreatic cancer patients. Myriad also stands to benefit from the growing support for genetic testing of breast cancer patients.
Chi-Med is setting a course straight for the Chinese FDA after its targeted therapy hit its PFS target ahead of schedule in neuroendocrine tumors.
Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.
Influenza is a wily foe. It shows up each winter having taken a slightly different guise to outwit our existing immune defenses, but always keeps up its sleeve an ability to shapeshift to an entirely form that could crash straight through them.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.